117 related articles for article (PubMed ID: 15667548)
21. [Arsenic and retinoic acid, toward targeted treatments of acute promyelocytic anemia?].
de Thé H
C R Seances Soc Biol Fil; 1998; 192(2):273-81. PubMed ID: 9759370
[TBL] [Abstract][Full Text] [Related]
22. Common defects of different retinoic acid resistant promyelocytic leukemia cells are persistent telomerase activity and nuclear body disorganization.
Nason-Burchenal K; Maerz W; Albanell J; Allopenna J; Martin P; Moore MA; Dmitrovsky E
Differentiation; 1997 Aug; 61(5):321-31. PubMed ID: 9342843
[TBL] [Abstract][Full Text] [Related]
23. Acute promyelocytic leukemia relapsing as secondary acute myelogenous leukemia with translocation t(3;21)(q26;q22) and RUNX1-MDS1-EVI1 fusion transcript.
Park TS; Choi JR; Yoon SH; Song J; Kim J; Kim SJ; Kwon O; Min YH
Cancer Genet Cytogenet; 2008 Dec; 187(2):61-73. PubMed ID: 19027486
[TBL] [Abstract][Full Text] [Related]
24. [All-trans retinoic acid therapy in acute promyelocytic leukemia--current status and prospect].
Kitamura K; Takeshita A; Ono R; Naoe T
Rinsho Ketsueki; 1996 Sep; 37(9):760-5. PubMed ID: 8914458
[No Abstract] [Full Text] [Related]
25. Molecular monitoring of minimal residual disease in acute promyelocytic leukemia by the polymerase chain reaction assay for the PML/RAR alpha (retinoic acid receptor-alpha) fusion transcript in patients treated with all-trans retinoic acid followed by chemotherapy.
Nemet D; Grahovac B; Labar B; Mrsić M; Radman I; Bogdanić V; Hitrec V; Zaher D; Aurer I; Sertić D
Haematologica; 1995; 80(3):238-40. PubMed ID: 7672716
[TBL] [Abstract][Full Text] [Related]
26. APL, a model disease for cancer therapies?
de Thé H; Chelbi-Alix MK
Oncogene; 2001 Oct; 20(49):7136-9. PubMed ID: 11704841
[No Abstract] [Full Text] [Related]
27. The PML-RAR alpha gene product of the t(15;17) translocation inhibits retinoic acid-induced granulocytic differentiation and mediated transactivation in human myeloid cells.
Rousselot P; Hardas B; Patel A; Guidez F; Gäken J; Castaigne S; Dejean A; de Thé H; Degos L; Farzaneh F
Oncogene; 1994 Feb; 9(2):545-51. PubMed ID: 8290265
[TBL] [Abstract][Full Text] [Related]
28. Promyelocytic leukemia-specific PML-retinoic acid alpha receptor fusion protein interferes with erythroid differentiation of human erythroleukemia K562 cells.
Grignani F; Testa U; Fagioli M; Barberi T; Masciulli R; Mariani G; Peschle C; Pelicci PG
Cancer Res; 1995 Jan; 55(2):440-3. PubMed ID: 7529139
[TBL] [Abstract][Full Text] [Related]
29. GTF2I-RARA is a novel fusion transcript in a t(7;17) variant of acute promyelocytic leukaemia with clinical resistance to retinoic acid.
Li J; Zhong HY; Zhang Y; Xiao L; Bai LH; Liu SF; Zhou GB; Zhang GS
Br J Haematol; 2015 Mar; 168(6):904-8. PubMed ID: 25284716
[No Abstract] [Full Text] [Related]
30. Detection of minimal residual disease in a patient with acute promyelocytic leukemia by RT-PCR: necessity of chemotherapy following ATRA therapy.
Sun T; Takatsuki H; Yamashita S; Yufu Y; Umemura T; Nishimura J; Nawata H
Fukuoka Igaku Zasshi; 1994 Feb; 85(2):52-6. PubMed ID: 8144129
[TBL] [Abstract][Full Text] [Related]
31. Granulocytic differentiation of human NB4 promyelocytic leukemia cells induced by all-trans retinoic acid metabolites.
Idres N; Benoît G; Flexor MA; Lanotte M; Chabot GG
Cancer Res; 2001 Jan; 61(2):700-5. PubMed ID: 11212271
[TBL] [Abstract][Full Text] [Related]
32. The t(15;17) translocation in acute promyelocytic leukemia.
Lavau C; Jansen J; Dejean A
Pathol Biol (Paris); 1995 Mar; 43(3):188-96. PubMed ID: 7675545
[TBL] [Abstract][Full Text] [Related]
33. Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL.
He LZ; Guidez F; Tribioli C; Peruzzi D; Ruthardt M; Zelent A; Pandolfi PP
Nat Genet; 1998 Feb; 18(2):126-35. PubMed ID: 9462740
[TBL] [Abstract][Full Text] [Related]
34. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia.
Grignani F; De Matteis S; Nervi C; Tomassoni L; Gelmetti V; Cioce M; Fanelli M; Ruthardt M; Ferrara FF; Zamir I; Seiser C; Grignani F; Lazar MA; Minucci S; Pelicci PG
Nature; 1998 Feb; 391(6669):815-8. PubMed ID: 9486655
[TBL] [Abstract][Full Text] [Related]
35. [Acute promyelocytic leukemia, histone deacetylase, and response to retinoids].
Jeanteur P
Bull Cancer; 1998 Apr; 85(4):301-3. PubMed ID: 9752292
[TBL] [Abstract][Full Text] [Related]
36. C-fms expression correlates with monocytic differentiation in PML-RAR alpha+ acute promyelocytic leukemia.
Riccioni R; Saulle E; Militi S; Sposi NM; Gualtiero M; Mauro N; Mancini M; Diverio D; Lo Coco F; Peschle C; Testa U
Leukemia; 2003 Jan; 17(1):98-113. PubMed ID: 12529666
[TBL] [Abstract][Full Text] [Related]
37. PML/RAR alpha + ATRA = CR. A comment on acute promyelocytic leukaemia: molecular pathology and treatment.
Dyer MJ
Eur J Cancer; 1994; 30A(5):573-4. PubMed ID: 8080665
[No Abstract] [Full Text] [Related]
38. ATRA and the specific RARα agonist, NRX195183, have opposing effects on the clonogenicity of pre-leukemic murine AML1-ETO bone marrow cells.
Chee LC; Hendy J; Purton LE; McArthur GA
Leukemia; 2013 Jun; 27(6):1369-80. PubMed ID: 23228968
[TBL] [Abstract][Full Text] [Related]
39. Genetics of APL and the molecular basis of retinoic acid treatment.
Casini T; Grignani F; Pelicci PG
Int J Cancer; 1997 Feb; 70(4):473-4. PubMed ID: 9033658
[No Abstract] [Full Text] [Related]
40. Missense mutations in the PML/RARalpha ligand binding domain in ATRA-resistant As(2)O(3) sensitive relapsed acute promyelocytic leukemia.
Marasca R; Zucchini P; Galimberti S; Leonardi G; Vaccari P; Donelli A; Luppi M; Petrini M; Torelli G
Haematologica; 1999 Nov; 84(11):963-8. PubMed ID: 10553155
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
